Adial Pharmaceuticals CEO Cary Claiborne set to depart after Sept. 17 annual meeting; CDO Matthew Davidson slated to succeed
ADIL•Leadership changes tied to Sept. 17 annual meeting
Adial Pharmaceuticals flagged a potential leadership reshuffle tied to a shareholder vote at its Sept. 17, 2026 annual meeting.
- CEO Cary Claiborne is expected to be removed promptly following the meeting if the proposals pass.
- Matthew Davidson, chief development officer and a board member, is slated to become president and CEO if the vote clears.
- CFO Vinay Shah is also expected to be removed promptly following the meeting if the proposals pass.
- Board turnover is anticipated, including resignations of legacy directors, though no final decisions have been made.
